Company Description
Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartere...
Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
Valuation
Price to Sales Ratio
24.22
Price to Book Ratio
3.15
Enterprise Value to EBITDA
-21.72
Enterprise Value to Sales
58.07
Total Debt to Enterprise Value
0.02
Efficiency
Revenue/Employee
362,380.00
Income Per Employee
-837,342.00
Receivables Turnover
5.06
Total Asset Turnover
0.12
Liquidity
Current Ratio
7.84
Quick Ratio
7.84
Cash Ratio
7.60
Profitability
Operating Margin
-230.60
Pretax Margin
-230.00
Net Margin
-231.07
Return on Assets
-27.47
Return on Equity
-36.79
Return on Total Capital
-34.51
Return on Invested Capital
-34.83
Capital Structure
Total Debt to Total Equity
2.13
Total Debt to Total Capital
2.09
Total Debt to Total Assets
1.83
Long-Term Debt to Equity
1.61
Long-Term Debt to Total Capital
1.58
Officers and Executives
| Name | Age | Officer Since | Title |
|---|---|---|---|
| Dr. Dinesh V. Patel | 62 | 2008 | President, CEO & Chief Financial Officer |
| Mr. Donald A. Kalkofen | 56 | 2019 | CFO & Principal Accounting Officer |
| Ms. Paula O’Connor | - | - | Senior Vice President-Clinical Development |
| Dr. Mark L. Smythe | - | 2006 | Chief Executive & Scientific Officer |
| Dr. David Y. Liu | 69 | 2013 | Chief Scientific Officer |
Insider Actions
| 12/21/2021 |
Dinesh V. Patel President and CEO; Director |
15,000 | Disposition at $32.14 per share. | 482,100 |
| 09/21/2021 |
Dinesh V. Patel President and CEO; Director |
40,000 | Derivative/Non-derivative trans. at $4.21 per share. | 168,400 |
| 08/17/2021 |
David Y. Liu Chief Scientific Officer |
14,779 | Disposition at $47.56 per share. | 702,889 |
| 08/17/2021 |
David Y. Liu Chief Scientific Officer |
10,000 | Derivative/Non-derivative trans. at $0.87 per share. | 8,700 |
| 02/26/2021 |
Dinesh V. Patel President and CEO; Director |
25,000 | Award at $0 per share. | 0 |
| 02/26/2021 |
Suneel Gupta Chief Development Officer |
12,000 | Award at $0 per share. | 0 |
| 02/26/2021 |
David Y. Liu Chief Scientific Officer |
10,000 | Award at $0 per share. | 0 |
| 02/26/2021 |
Samuel R. Saks Chief Medical Officer |
12,000 | Award at $0 per share. | 0 |
| 02/26/2021 |
Donald A. Kalkofen Chief Financial Officer |
7,500 | Award at $0 per share. | 0 |
| 02/11/2021 |
Sarah B. Noonberg Director |
3,700 | Disposition at $25.09 per share. | 92,833 |
| 02/11/2021 |
Sarah B. Noonberg Director |
3,700 | Award at $6.98 per share. | 25,826 |
| 02/10/2021 |
Sarah B. Noonberg Director |
400 | Disposition at $26.04 per share. | 10,416 |
| 02/10/2021 |
Sarah B. Noonberg Director |
4,300 | Disposition at $25.42 per share. | 109,306 |
| 02/10/2021 |
Sarah B. Noonberg Director |
4,700 | Award at $6.98 per share. | 32,806 |
| 01/19/2021 |
Dinesh V. Patel President and CEO; Director |
24,846 | Disposition at $24.6 per share. | 611,211 |
| 01/19/2021 |
Dinesh V. Patel President and CEO; Director |
13,000 | Derivative/Non-derivative trans. at $4.21 per share. | 54,730 |
| 08/11/2020 |
Chaitan S. Khosla Director |
2,499 | Disposition at $17.19 per share. | 42,957 |
| 08/11/2020 |
Chaitan S. Khosla Director |
2,499 | Derivative/Non-derivative trans. at $1.89 per share. | 4,723 |
| 04/29/2020 |
Dinesh V. Patel President and CEO; Director |
2,000 | Gift at $0 per share. | 0 |
| 03/20/2020 |
Dinesh V. Patel President and CEO; Director |
10,000 | Derivative/Non-derivative trans. at $1.89 per share. | 18,900 |
MarketWatch News on PTGX
-
5 Biotech Stocks That Are Bucking the Selloff
- Barron's Online
-
Protagonist Therapeutics upgraded to overweight from neutral at J.P. Morgan
- Tomi Kilgore
-
Protagonist Therapeutics downgraded to neutral from overweight at J.P. Morgan
- Tomi Kilgore
-
Biotech stocks are a buy — especially these 18 picks
- Michael Brush
-
Protagonist Therapeutics initiated at overweight with $35 price target at JPMorgan
- Tonya Garcia
-
Protagonist Therapeutics stock price target raised to $29 vs. $13 at Instinet
- Ciara Linnane
-
Protagnoist Therapeutics stock price target raised to $17 from $11 at Stifel Nicolaus
- Tomi Kilgore
-
Protagonist Therapeutics upgraded to buy from hold at Stifel Nicolaus
- Tomi Kilgore
-
- Barron's Online
-
A Biotech Collapses: Is Buying Now ‘Futile’?
- Barrons Blogs
-
Protagonist Therapeutics started at buy with $32 stock price target at Stifel Nicolaus
- Tomi Kilgore
-
- Barron's Online
Other News on PTGX
-
10-Q: PROTAGONIST THERAPEUTICS, INC
- Edgar Online - (EDG = 10Q, 10K)
-
Wall Street Breakfast: What Moved Markets
- Seeking Alpha
-
New Strong Sell Stocks for October 14th
- Zacks.com
-
CEI, ANY and HNRG among mid-day movers
- Seeking Alpha
-
APRN, CEI and GOTU among mid-day movers
- Seeking Alpha
- Loading more headlines...
